Home » Stocks » TERN

Terns Pharmaceuticals, Inc. (TERN)

Stock Price: $17.42 USD -1.92 (-9.93%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 437.47M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 15.16M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $17.42
Previous Close $19.34
Change ($) -1.92
Change (%) -9.93%
Day's Open 18.92
Day's Range 17.22 - 18.92
Day's Volume 40,283
52-Week Range 14.58 - 28.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

9 hours ago - GlobeNewsWire

FOSTER CITY, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-mo...

3 weeks ago - GlobeNewsWire

FOSTER CITY, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

2 months ago - GlobeNewsWire

-Terns ended 4Q 2020 with $75 million in cash and cash equivalents and completed an upsized initial public offering in February 2021, raising approximately $147 million in gross proceeds to support oper...

2 months ago - GlobeNewsWire

This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.

Other stocks mentioned: GILD, ICPT, MDGL, NVS, PFE
2 months ago - The Motley Fool

-TERN-501 is designed to have high metabolic stability, enhanced liver distribution and high selectivity for THR- β-

2 months ago - GlobeNewsWire

FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

3 months ago - GlobeNewsWire

FOSTER CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

4 months ago - GlobeNewsWire

FOSTER CITY, Calif. -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...

4 months ago - GlobeNewswire

FOSTER CITY, Calif.--Terns Pharmaceuticals, Inc. (“Terns” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy cand...

4 months ago - Business Wire

Terns Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

Terns Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for NASH, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

4 months ago - NASDAQ

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy...

5 months ago - Business Wire

About TERN

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. NASH is a severe form of non-alcoholic fatty liver disease, or NAFLD, that affects up to 15 million people in the United States, and up to 6% of the global population, for which there is currently no approved therapy in the United States or Europe. NASH is a multifaceted disease that involves thre... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Senthil Sundaram
Employees
30
Stock Exchange
NASDAQ
Ticker Symbol
TERN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for TERN is 29.00, which is an increase of 66.48% from the latest price.

Price Target
$29.00
(66.48% upside)